On Friday, Shares of Zynga, Inc. (NASDAQ:ZNGA), surged 7.76% to $2.64.
Zynga declared it has reached a multi-year agreement with Warner Bros. Interactive Entertainment to license the iconic brand, Willy Wonka and the Chocolate Factory, for its Social Casino games. As a first step, Zynga will bring this beloved brand to life with a Willy Wonka and the Chocolate Factory-themed social slots game, slated to launch worldwide across mobile and web in 2016.
Zynga’s Willy Wonka and the Chocolate Factory slots game will marry the whimsical world of Wonka with classic social slots gameplay to create an authentic entertainment experience for consumers. The game is being developed by the team behind Zynga’s Hit It Rich! Slots and Wizard of Oz Slots, both of which are presently Top 10 Grossing Casino games on the Apple App Store. Hit It Rich! Slots, accessible for free download on the App Store for iPhone, iPad and iPod touch, Google Play, Amazon Kindle Fire HD and Facebook, delivers players new ways to play with a multi-media social slots experience featuring more than 25 of their favorite entertainment brands.
Zynga Inc. develops, markets, and operates online social games as live services played on the Internet, social networking sites, and mobile platforms in the United States, Asia, and Europe.
Shares of PayPal Holdings, Inc. (NASDAQ:PYPL), inclined 0.72% to $39.13, during its last trading session.
PayPal Holdings declared John D. Rainey is joining the digital payments leader as its new Chief Financial Officer (CFO), effective August 24, 2015. Rainey joins PayPal from United Continental Holdings, Inc. where he was Executive Vice President and CFO at United Airlines. Rainey brings with him an extensive background in corporate finance, treasury, financial planning and analysis, tax, investor relations, planned planning and risk administration together with a deep appreciation for PayPal and its unique position driving the global transformation of money.
Rainey will lead PayPal’s financial operations, regional finance teams and investor relations. He will report directly to Schulman. He will succeed Patrick Dupuis, who has served as PayPal’s CFO for five years.
Dupuis will remain at PayPal and will continue to report directly to Schulman in the newly created role of Senior Vice President, Simplicity, Quality and Productivity. In this capacity, Dupuis will lead a corporate-wide transformation initiative designed to drive PayPal’s productivity, service quality and customer experience.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, in addition to at offline retail locations through a range of payment solutions across company’s payments platform, counting PayPal, PayPal Credit, Venmo, and Braintree products.
Finally, TherapeuticsMD, Inc. (NYSEMKT:TXMD), ended its last trade with -7% loss, and closed at $6.78.
TherapeuticsMD declared its second quarter financial results for the period ended June 30, 2015.
Second Quarter and Recent Developments
- Net revenue for the company’s prescription prenatal vitamin business raised to about $4.8 million for the second quarter of 2015 contrast with about $3.8 million for the second quarter of 2014.
- Net loss was about $27.2 million for the second quarter of 2015, contrast with about $10.9 million for the second quarter of 2014, reflecting costs associated with the company’s continued enrollment of patients in two phase 3 clinical trials for its novel hormone therapy product candidates.
- Accomplished patient enrollment in the Rejoice Trial, a phase 3 clinical trial of TX-004HR (estradiol in VagiCap™), an applicator-free vaginal estradiol product candidate for the treatment of moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
- Continued recruitment of patients for the Replenish Trial, a phase 3 clinical trial of TX-001HR, a combination estradiol and progesterone product candidate, for the treatment of moderate to severe vasomotor symptoms due to menopause.
- Ended the quarter with $67.2 million in cash and no debt.
- Accomplished an underwritten public offering of common stock in July 2015 that resulted in net proceeds to the company of about $32.2 million.
- Grew the company’s intellectual property portfolio to a current total of 111 patent filings, of which 61 were filed in international jurisdictions, counting three allowed and 11 issued U.S. patents.
- Supported scientific abstracts and presentations at meetings of the American College of Obstetricians and Gynecologists (ACOG) and the European Society of Menopause and Andropause.
- Continued to develop relationships with key medical and industry organizations.
TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
